Compare AbbVie Inc (ABBV) vs Arko Corp. (ARKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Arko Corp. — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Arko Corp. trades at $8.07 (market cap $880.66M). The key difference: AbbVie Inc is far larger — about 510.9× Arko Corp.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | ARKO | |
|---|---|---|
Market Cap | $449.91B | $880.66M |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $8.64 |
52-Week Low | $184.85 | $3.82 |
Enterprise Value | $513.38B | $3.05B |
Dividend Yield | 2.72% | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
ARKO trades at $7.85, down 2.36% today, with a bullish technical signal from moving averages. The company reported Q1 2026 earnings of -$0.07 per share, beating expectations, but revenue has declined from $9.4B in 2023 to $7.6B in 2025. Net income margin remains thin at 0.38%, while the P/E ratio of 39.75 suggests high earnings expectations relative to current profits. Recent news highlights ARKO as a defensive pick amid inflation concerns.
The outlook is mixed: positive technical momentum and defensive stock characteristics offer upside, but weak revenue growth and low profitability pose risks. All covering analysts rate it Hold, indicating caution. Investment appeal hinges on margin improvement and stable cash flow to support dividends, though high debt and economic sensitivity remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →
